Zymeworks Inc. (NASDAQ: ZYME) announced results from a phase 1 study of ZW191, an antibody-drug conjugate targeting folate receptor alpha ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE